Results: The Alliance has developed a unique formulation solution combining foam properties and reduced interfacial tension, even in high temperature and harsh conditions of injection brine. Coreflood experiments show that foam exists and propagates in fractures and aqueous formulation enters the matrix so that the reduced interfacial tension can boost the recovery factor of the matrix. These conclusions are supported by laboratory work and simulation models. Advanced EOR Foams for Naturally Fractured Carbonates

Adjuvants의 역할과 종류

Hand, foot and mouth disease (HFMD) is a highly contagious viral infection affecting young children during the spring to fall seasons. Recently, serious outbreaks of HFMD were reported frequently in the Asia-Pacific region, including China and Korea. The symptoms of HFMD are usually mild, comprising fever, loss of appetite, and a rash with blisters, which do not need specific treatment. However, there are uncommon neurological or cardiac complications such as meningitis and acute flaccid paralysis that can be fatal. HFMD is most commonly caused by infection with coxsackievirus A16, and secondly by enterovirus 71 (EV71). Many other strains of coxsackievirus and enterovirus can also cause HFMD. Importantly, HFMD caused by EV71 tends to be associated with fatal complications. Therefore, there is an urgent need to protect against EV71 infection. Development of vaccines against EV71 would be the most effective approach to prevent EV71 outbreaks. Here, we summarize EV71 infection and development of vaccines, focusing on current scientific and clinical progress.

/pdf/enterovirus-71-infection-and-vaccines-2sbxt06b81.pdf

Enterovirus 71 infection and vaccines

On December 3rd 2015, the China Food and Drug Administration (CFDA) approved the first inactivated Enterovirus 71 (EV71) whole virus vaccine for preventing severe hand, foot and mouth disease (HFMD). As one of the few preventive vaccines for children's infectious diseases generated by the developing countries in recent years, EV71 vaccine is a blessing to children's health in China and worldwide. However, there are still a few challenges facing the worldwide use of EV71 vaccine, including the applicability against various EV71 pandemic strains in other countries, international requirements on vaccine production and quality control, standardization and harmonization on different pathogen monitoring and detecting methods, etc. In addition, the affordability of EV71 vaccine in other countries is a factor to be considered in HFMD prevention. Therefore, with EV71 vaccine commercially available, there is still a long way to go before reaching effective protection against severe HFMD after EV71 vaccines enter the market. In this paper, the bottlenecks and prospects for the wide use of EV71 vaccine after its approval are evaluated.

EV71 vaccine, a new tool to control outbreaks of hand, foot and mouth disease (HFMD)

Enterovirus 71 (EV71) and coxsackievirus A16 (CA16) are the predominant pathogens causing outbreaks of hand, foot and mouth disease (HFMD) worldwide. Other human enterovirus A (HEV-A) serotypes tend to cause only sporadic HFMD cases. However, since a HFMD caused by coxsackievirus A6 broke out in Finland in 2008, CA6 has been identified as the responsible pathogen for a series of HFMD outbreaks in Europe, North America and Asia. Because of the severity of the clinical manifestations and the underestimated public health burden, the epidemic of CA6-associated HFMD presents a new challenge to the control of HFMD. This article reviewed the epidemic characteristics, molecular epidemiology, clinical features and laboratory diagnosis of CA6 infection. The genetic evolution of CA6 strains associated with HFMD was also analyzed. It indicated that the development of a multivalent vaccine combining EV71, CA16 and CA6 is an urgent necessity to control HFMD.

Coxsackievirus A6: a new emerging pathogen causing hand, foot and mouth disease outbreaks worldwide

The limits of the nuclear landscape explored by the relativistic continuum Hartree–Bogoliubov theory

Enterovirus 71 (EV71) and Coxsackievirus A16 (CVA16) have caused severe epidemics of hand, foot and mouth disease (HFMD) in the Asia Pacific in recent years, particularly in infants and young child...

https://www.tandfonline.com/doi/pdf/10.4161/hv.29823

Evaluation of monovalent and bivalent vaccines against lethal Enterovirus 71 and Coxsackievirus A16 infection in newborn mice.

Streptococcus pneumoniae is an important pathogen accounting for a large number of deaths worldwide. Due to drawbacks of the current polysaccharide-based vaccine, the most promising way to generate an improved vaccine may be to utilize protection-eliciting pneumococcal proteins. Pneumococcal surface adhesin A (PsaA) and pneumococcal surface protein A (PspA) are two vaccine candidates which have been evaluated against S. pneumoniae infection in animal models or human clinical trials with encouraging results. In this study, the efficacy of the fusion protein PsaA-PspA, which includes PsaA part and PspA part, in inducing immunoprotective effects against fatal pneumococcal challenge was evaluated in an animal model. PspA part of PsaA-PspA fusion protein contains both family1 N-terminal region and family 2 N-terminal clade-defining region of PspA. Immunization with the PsaA-PspA fusion protein induced high levels of antibodies against both PsaA and PspA, which could bind to intact S. pneumoniae strains bearing different PspAs. Ex vivo stimulation of splenocytes from mice immunized with PsaA-PspA induced IL-17A secretion. Mice immunized with PsaA-PspA showed reduced S. pneumoniae levels in the blood and lungs compared with the PBS group after intranasal infection. Finally, mice immunized with PsaA-PspA fusion proteins were protected against fatal challenge with pneumococcal strains expressing different PspAs regardless of the challenge route. These results support the PsaA-PspA fusion protein as a promising vaccine strategy, as demonstrated by its ability to enhance the immune response and stimulate production of high titer antibodies against S. pneumoniae strains bearing heterologous PspAs, as well as confer protection against fatal challenge with PspA family 1 and family 2 strains.

Protective Immune Responses Elicited by Fusion Protein Containing PsaA and PspA Fragments

Respiratory syncytial virus (RSV) is a leading cause of lower respiratory illness, particularly in infants, the elderly, and immunocompromised adults. There is no licensed commercial vaccine against RSV. Importantly, formalin-inactivated RSV vaccines mediate enhanced respiratory disease. RSV fusion (F) protein with pre-fusion conformation is a promising candidate subunit vaccine. However, some problems remain to be solved, such as low immunogenicity and humoral immunity bias. Adjuvants can effectively enhance and adjust vaccine immune responses. In this study, we formulated pre-fusion RSV-F protein with the adjuvants, Alhydrogel, MF59, AS03, AS02, and glycol chitosan (GCS). We then conducted head-to-head comparisons of vaccine-induced immune responses in BALB/c mice. All adjuvanted vaccines enhanced antigen-specific and neutralizing antibody titers and viral clearance and gave an order of adjuvant activity: AS02 > AS03, MF59 > GCS, and Alhydrogel. Among them, AS02 elicited the highest antibody expression, which persisted until week 18. Moreover, AS02 significantly enhanced Th1 type immune response in immunized mice. Mice in the AS02 group also showed faster recovery from viral attacks in challenge tests. Further transcriptome analysis revealed that AS02 regulates immune balance by activating TLR-4 and promotes Th1-type immune responses. These results suggest that AS02 may be an excellent candidate adjuvant for RSV-F subunit vaccines. This study also provides valuable information regarding the effect of other adjuvants on immune responses of RSV-F subunit vaccines.

/pdf/respiratory-syncytial-virus-f-subunit-vaccine-with-as02-4ec8vtfq7l.pdf

Respiratory Syncytial Virus F Subunit Vaccine With AS02 Adjuvant Elicits Balanced, Robust Humoral and Cellular Immunity in BALB/c Mice

High-spin states of $^{138}\mathrm{Pm}$ have been populated using the $^{124}\mathrm{Te}(^{19}\mathrm{F},\phantom{\rule{0.28em}{0ex}}5\mathrm{n})^{138}\mathrm{Pm}$ reaction at a beam energy of 105 MeV. A new positive-parity side band with the same $\ensuremath{\pi}{h}_{11/2}\ensuremath{\bigotimes}\ensuremath{\nu}{h}_{11/2}$ configuration as that of the yrast band is observed in $^{138}\mathrm{Pm}$. The properties of the two positive-parity bands show general agreement with the fingerprints of chiral rotation and thus these two bands are suggested to be candidates for near degenerate chiral doublet bands. Besides, odd-even spin staggering of the $\ensuremath{\pi}{h}_{11/2}\ensuremath{\bigotimes}\ensuremath{\nu}{h}_{11/2}$ bands is studied systematically in odd-odd Cs, La, Pr, and Pm isotopes. As a result of this study we suggest that the spin value of lowest observed state of the yrast band be reassigned as 9 in $^{138}\mathrm{Pm}$. This new spin assignment is also supported by the argument of alignment additivity.

Candidate chiral doublet bands in Pm 138

The candidate chiral doublet bands in ${}^{128}$La have been searched for through the ${}^{118}$Sn(${}^{14}$N, 4n)${}^{128}$La reaction at a beam energy of 69 MeV. A positive-parity sideband with the same configuration as that of the yrast band has been identified. The positive-parity and spins of the sideband have been assigned based on the $\ensuremath{\Delta}I=1$ mixed $M1/E2$ and $E2$ characters of the linking transitions between the sideband and the yrast band. The properties of the sideband and the yrast band are discussed. The newly identified sideband and the yrast band are suggested to form the candidate of the near degenerate chiral doublet bands.

Jingcai Lu

Papers

Evaluation of monovalent and bivalent vaccines against lethal Enterovirus 71 and Coxsackievirus A16 infection in newborn mice.

Protective Immune Responses Elicited by Fusion Protein Containing PsaA and PspA Fragments

Respiratory Syncytial Virus F Subunit Vaccine With AS02 Adjuvant Elicits Balanced, Robust Humoral and Cellular Immunity in BALB/c Mice

Candidate chiral doublet bands in Pm 138

Candidate chiral doublet bands in 128 La